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ABSTRACT
Objectives To determine if the length of interval between
breast conserving surgery and start of radiotherapy
affects local recurrence and to identify factors that might
be associated with delay in older women with breast
cancer.
Design Retrospective cohort analysis with Cox
proportional hazards models to study the association
between time to radiotherapy and local recurrence, and
propensity score and instrumental variable analyses to
confirm findings. Logistic regression investigated factors
associated with later start of radiotherapy.
Setting Linked database (Surveillance, Epidemiology,
and End Results Program-Medicare) in the United States
Participants 18050 women aged over 65 with stage 0-II
breast cancer diagnosed in 1991-2002 who received
breast conserving surgery and radiotherapy but not
chemotherapy.
Main outcome measure Local recurrence.
Results Median time from surgery to start of radiotherapy
was 34 days, with 29.9% (n=5389) of women starting
radiotherapy after six weeks. Just over 4% (n=734) of the
cohort experienced a local recurrence. After adjustment
for clinical and sociodemographic factors, intervals over
six weeks were associated with increased likelihood of
local recurrence (hazard ratio 1.19, 95% confidence
interval 1.01 to 1.39, P=0.033). When the interval was
modelled continuously (assessing accumulation of risk
by day), the effect was statistically stronger (hazard ratio
1.005 per day, 1.002 to 1.008, P=0.004). Propensity
score and instrumental variable analysis confirmed these
findings. Instrumental variable analysis showed that
intervals over six weeks were associated with a 0.96%
increase in recurrence at five years (P=0.026). In
multivariable analysis, starting radiotherapy after six
weeks was significantly associated with positive nodes,
comorbidity, history of low income, Hispanic ethnicity,
non-white race, later year of diagnosis, and residence
outside the southern states of the US.
Conclusions There is a continuous relation between the
interval from breast conserving surgery to radiotherapy
and local recurrence in older women with breast cancer,
suggestingthatstartingradiotherapyas soonas possible
could minimise the risk of local recurrence. There are
considerable disparities in time to starting radiotherapy
after breast conserving surgery. Regions of the US known
to have increased rates of breast conserving surgery had
longer intervals before radiotherapy, suggesting
limitations in capacity. Given the known negative impact
oflocalrecurrenceonsurvival,mechanismstoameliorate
disparities and policies regarding waiting times for
treatment might be warranted.
INTRODUCTION
Thepasttwodecadeshavewitnessedanincreaseinthe
use of radiotherapy and in waiting times to start radio
therapy.
1-4Waitinglistsforradiotherapyarenowcom-
mon in many parts of the world.
4-8 Longer times to
radiotherapy are a result of rise in demand—from
intensified screening, greater number of diagnoses of
cancer in an ageing population, and expanding indica-
tions for and increasing technological complexity of
treatment—that outstrips the supply of equipment
and services.
Althoughfourtosixweeksisgenerallycitedasarea-
sonable interval between surgery and radiotherapy,
9
evidence regarding the effect of waiting times in
patients in breast cancer is mixed. Some studies have
foundnoassociationbetweentimetoradiotherapyand
local recurrence after breast conserving surgery,
10-12
while others have reported increased recurrence
among patients with longer intervals.
13-16 Because
local recurrence after breast conserving surgery and
radiotherapy is a relatively uncommon event, the
inconsistency across studies might reflect variable
power to detect a difference. Moreover, many of these
studiesdichotomisedtimetoradiotherapyintheirana-
lysis but used different thresholds, leaving unanswered
the question of whether there is a point before which it
is safe to defer radiotherapy, or if the relation between
interval and recurrence is continuous.
Theneedforaclearanswerregardingwhetherinter-
valtoradiotherapyaffectslocalrecurrenceisespecially
criticalgiventhat meta-analysesofrandomisedstudies
have now unequivocally shown a link between local
recurrence and decreased survival in breast cancer.
17
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ods after surgery would provide the most definitive
evidence regarding the effect of the interval from sur-
gery to radiotherapy on local recurrencein breast can-
cer but would be unethical. We therefore used the
linked Surveillance, Epidemiology, and End Results
Program-Medicare database, the largest US popula-
tion based data source within oncology, to describe
the relation between interval to radiotherapy and
recurrence of breast cancer.
METHODS
Data sources
The linked database we used contains information
fromtheSurveillance,Epidemiology,andEndResults
Program up to 2002 and Medicare claims up to 2005.
Medicare is a social insurance programme adminis-
teredbytheUSgovernmentthatprovideshealthinsur-
anceforpeopleaged65andolder,thosewithendstage
renal disease, and some people with disabilities. Med-
icare operates as a single payer healthcare system and
is the primaryhealthinsurerfor 97% ofthe population
aged 65 and older. Medicare claims are the only
national population based data in the United States
that reliably and exhaustively capture medical treat-
ment and outcomes and have therefore been used
extensivelytostudythequalityandoutcomesofhealth
care. The Surveillance, Epidemiology, and End
Results Program of the National Cancer Institute is
the authoritative source of information on incidence
ofandsurvivalfromcancerintheUS.Theprogramme
collectsinformationontumoursanddemographicsfor
all incident cancer cases in people living in California,
Connecticut,Hawaii,Iowa,Kentucky,Louisiana,New
Jersey, New Mexico, Utah, rural Georgia, and metro-
politan areas of Atlanta, Detroit, and Seattle. New Jer-
sey, Kentucky, Louisiana, and partsof California were
in the programme from 2000. The programme regis-
tries, which cover 26% of the population, were
assembled by the National Cancer Institute for their
quality and to facilitate adequate representation of
minority populations to ensure applicability. There-
fore, the population covered by the programme is
comparable with the general US population with
regardtomeasuresofpovertyandeducation.Inpatient
andoutpatientMedicareclaimsand physician,labora-
tory, durable medical equipment, home health, and
hospice billings have been linked to programme data
for patients aged over 65.
18 The US Institute of Medi-
cine identified the linked database as one of the few
population based data resources available for analyses
of quality of cancer care, and the programme popula-
tion well represents the US population.
19 Sociodemo-
graphic information at both the census tract and zip
code level (from the 2000 census) is also included.
Cohort selection
The cohort consisted of women with unilateral patho-
logicallyconfirmedstage0-IIbreastcancer(American
JointCommitteeonCancer)diagnosedfrom1January
1991 to 31 December 2002 at the age of 65 or older.
TheywerealllivinginaregioncoveredbytheSurveil-
lance, Epidemiology, and End Results Program and
had received breast conserving surgery and radio-
therapy. We restricted the cohort to patients who had
not received chemotherapy within six months of sur-
geryaschemotherapyisgenerallyadministeredbefore
radiotherapy and might exerta directeffect onthe risk
of local recurrence.
20
WeexcludedpatientsenrolledinMedicareforrenal
diseaseor disability astheymightdiffer fromthose eli-
gible for Medicare on the basis of age. We also
removed those with previous cancers, death dates
that differed by more than three months in the two
data sources, diagnoses made from death certificates
orautopsy,andmissingdatesofdiagnosis.Continuous
Medicare (part A and part B) cover and no enrolment
in a health maintenance organisation were required
from month of diagnosis through to death or the end
of the study (31 December 2005).
Thecohortwasrestrictedtopatientswhounderwent
radiotherapy within six months after their last breast
conserving surgery. To avoid misclassification, we
excluded women who had a subsequent diagnosis of
cancer, local recurrence, or mastectomy within this
six month period. We also restricted the analysis to
those patients who survived at least two years after
radiotherapy (96.6% of the cohort) to ensure sufficient
time for diagnosis and treatment of local recurrence.
Breast conserving surgery was identified in Medi-
care claims with current procedural terminology
codes 19120, 19125-6, 19160, and 19162 from the
American Medical Association, ICD-9-CM (inter-
national classification of diseases, ninth revision, clin-
ical modification) procedural codes 85.20-85.23, or in
hospital diagnosis related group codes 259-260. In
Medicare records we identified radiotherapy with cur-
rent procedural terminology radiation delivery codes
77401-77418 or ICD-9-CM procedure codes 92.20-
92.29. Radiotherapy planning was identified with cur-
rent procedural terminology codes 77260-77399.
Definition of interval and local recurrence
We used the last date of breast conserving surgery
within the interval from six months before to six
months after diagnosis as the date of surgery. The
start date for radiotherapy was determined by the
date of the first radiotherapy delivery code. We used
radiotherapy delivery dates linked to ICD-9-CM pro-
cedure codes when available and dates derived from
current procedural terminology codes otherwise. To
enhance the accuracy of the first radiotherapy date,
we restricted the cohort to patients with a treatment
planning current procedural terminology date from
21 days before to seven days after first radiotherapy
delivery date. The number of days between the start
date and last breast conserving surgery defined the
interval from surgery to radiotherapy.
A local recurrence was defined as mastectomy in
Medicare claimsor a secondpathologically confirmed
RESEARCH
page 2 of 8 BMJ | ONLINE FIRST | bmj.comdiagnosis of ipsilateral breast cancer in the Surveil-
lance, Epidemiology, and End Results Program, as in
Smith et al,
21 or a secondary breast cancer diagnosis
(ICD-9-CM 198.81) more than six months from the
last breast conserving surgery.
Patients’ characteristics
Explanatory variables used in this study included year
of diagnosis, characteristics of tumour, other clinical
characteristics (age at diagnosis, comorbidities), treat-
ments received (nodal examinations, hormonal ther-
apy), sociodemographic factors, and distance to
nearest radiation treatment facility.
Weincludedyearofdiagnosis(1991-2002)asacate-
gorical and continuous variable. Age at diagnosis was
categorised as <70, 70-<75, 75-<80, 80-<85, and ≥85
and was also studied as a continuous variable. Vari-
ables for tumour characteristics were categorised
according to clinical cut offs defined a priori.
Comorbidities were identified with diagnostic billing
codes for specific health conditions during the year
before diagnosis with the Deyo implementation
22 of
the Charlson score
23 and applied to inpatient and out-
patient claims.
24 The Charlson score was then cate-
gorised as 0, 1, 2, or ≥3. Patients without any
comorbidity claims during the 13 months before diag-
nosis were classified as having no comorbidity. We
performed a sensitivity analysis excluding these
patients to ensure that results did not change. Nodal
examinationanduseofhormonaltherapywereidenti-
fied from the Surveillance, Epidemiology, and End
Results Program.
Tomeasuresocioeconomicstatusweprioritisedcen-
sustractmedianincomeandpercapitaincomeoverzip
code to develop fifths. As an individual measure, we
classified a patient as having a “personal history of
lowincome”ifshewaspartofthestatebuy-ininsurance
programme during 1986-2005. We categorised the
cancer registries into regions of the US: west (Califor-
nia, Hawaii, New Mexico, Seattle, Utah); Midwest
(Detroit, Iowa), northeast (Connecticut and New Jer-
sey), and south (Atlanta, rural Georgia, Kentucky,
Louisiana). Race was classified as white, black, or
other, and ethnicity as Hispanic or non-Hispanic. Dis-
tancetoa radiotherapyfacilitywasdetermined withan
algorithm that calculates the distance between the zip
code of the patient’s residence and that of the closest
radiotherapy facility included in the 2000 American
Hospital Association’s annual survey of hospitals.
25
Main statistical analyses
Statistical analyses were conducted with SAS for Win-
dows (version 9.1.3; SAS Institute, Cary, NC). We stu-
diedtheinfluenceofintervaltoradiotherapyontimeto
local recurrence of breast cancer using a Cox propor-
tionalhazardsmodel.Patientswerecensoredatthefirst
evidence of distant disease, death, or end of the study
(31 December 2005). The final multivariable Cox
model included significant variables, as well as factors
identified a priori as potential predictors: treatment
year, age at diagnosis, and pathology (preinvasive ver-
sus invasive). We studied two definitions of time to
radiotherapy—interval dichotomised at six weeks and
days to radiotherapy—in separate multivariable mod-
els. We chose six weeks as the threshold interval as it
represents a cited benchmark for the initiation of radio
therapy.
926Wealsoexaminedintervaldichotomisedat
different thresholds in two week increments.
In sensitivity analyses, we examined the effect of
excluding patients with preinvasive carcinoma (stage
0) or ductal carcinoma in situ. To gain insight into
potential factors that lengthen the interval to radio-
therapy, we performed multivariable logistic regres-
sion using a forwards and backwards elimination
algorithm to determine the final multivariable model.
We did not include receipt of hormone therapy, as
identified by the Surveillance, Epidemiology, and
End Results Program, as an explanatory variable in
this analysis as reasons for omission could be related
Table 1 |Demographic characteristics of population studied
(n=18 050)
Characteristic No (%) of women
Age at diagnosis (years):
≥85 643 (3.6)
≥80-<85 2221 (12.3)
≥75-<80 4437 (24.6)
≥70-<75 5557 (30.8)
<70 5192 (28.8)
Race:
White 16 570 (91.8)
Black 807 (4.5)
Other 673 (3.7)
Hispanic:
No 17 494 (96.9)
Yes 556 (3.1)
Region:
Midwest 3527 (19.5)
West 8800 (48.8)
Northeast 3834 (21.2)
South 1889 (10.5)
Urban:
No 1086 (6.0)
Yes 16 964 (94.0)
History of low income:
No 16 230 (89.9)
Yes 1820 (10.1)
Charlson score:
0 13 860 (76.8)
1 3146 (17.4)
2 583 (3.2)
≥3 461 (2.6)
Married at diagnosis:
No 8809 (48.8)
Yes 9241 (51.2)
Distance to nearest radiotherapy facility (miles):
≥25/unknown 2125 (11.8)
<25 15 925 (88.2)
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carried out a secondary analysis studying the inter-
action of treatment year with regions of the US.
Confirmatory analyses
Weperformedapropensityscoreanalysistoassessthe
consistency of the association between interval to
radiotherapy and local recurrence and to control for
possible differences in the distribution of confounders
between the group of women who experienced
increased time to radiation and those who did not. All
available variables were used to create a propensity
score to predict the likelihood of having an interval
greater than six weeks. We studied the influence of
time to radiotherapy with models that controlled for
this score and performed the analyses separately
within similar propensity strata.
To further assess the validity of our findings and
adjust for unmeasured confounders, we also per-
formed an instrumental variable analysis, an econo-
metric method used to remove the effects of hidden
bias in observational studies.
27 An instrumental vari-
able must fulfil two criteria: correlation with treatment
(time to radiotherapy in our analysis) and lack of inde-
pendentaffectonoutcome(recurrenceinouranalysis).
Insteadofdirectlycomparingpatientswhoexperience
delaywiththosewhodonot,whichmightresultinbias,
the instrumental variable then acts to “randomise”
patients into groups that differ in their likelihood of
experiencing treatment delay. Instrumental variable
models provide adjusted effect estimates at one time
point and on an absolute rather than a relative scale.
We selected distance to radiotherapy facility as our
instrumental variable and restricted the analysis to
patients with known travel distance. For the dichoto-
mousoutcomerequiredbythisanalysis,wechoselocal
recurrence by five years and restricted the analysis to
patients with five years of follow-up (n=9053). We
separated patients into two groups, based on whether
they lived within or further than 4.79 miles (about 8
km) (median travel distance) of the nearest radiation
facility. Patients living closer were less likely to have
an interval to radiotherapy of over six weeks (25.2% v
27.5%,P=0.011).Forthisanalysis,weusedanon-para-
metric two stage least squares model to predict longer
interval to radiotherapy. We then used local recur-
rence by five years as the outcome of interest and con-
trolled for all factors significant in the proportional
hazards model for local recurrence. In this technique,
outcomes are reported for “marginal” patients—those
expected to experience longer time to radiotherapy if
they lived further from a radiation facility but not if
they lived close to the treatment facility.
RESULTS
Among 18050 women with stage 0-II breast cancer
(16.9% stage 0, 67.4% stage I, 15.6% stage II) who
underwent breast conserving surgery, the median
time from last breast surgery to start of radiotherapy
was 34 days (range 1-181) and the median follow-up
Table 2 |Characteristics of cancer and treatment in
population studied (n=18 050)
Characteristic No (%) of women
Stage:
0/DCIS 3058 (16.9)
I 12 171 (67.4)
II 2821 (15.6)
Tumour size (cm):
0-2 14 971 (82.9)
>2-5 1967 (10.9)
>5 115 (0.6)
Not stated 997 (5.5)
No of affected nodes:
0 11 111 (61.6)
1-3/affected, but number not known 1130 (6.3)
≥4 101 (0.6)
Unknown 54 (0.3)
Not examined 5654 (31.3)
Oestrogen receptor status:
Positive 12 077 (66.9)
Borderline 28 (0.2)
Negative 1239 (6.9)
Not done 4706 (26.1)
Progesterone receptor status:
Positive 10 081 (55.9)
Borderline 100 (0.6)
Negative 2928 (16.2)
Not done 4941 (27.4)
Tumour grade:
Well differentiated 4515 (25.0)
Moderately differentiated 7090 (39.3)
Poorly differentiated 3043 (16.9)
Unknown 3402 (18.9)
Histology:
Ductal 12 165 (67.4)
Lobular 1329 (7.4)
Mixed ductal/lobular 1127 (6.2)
Tubular/medullary/mucinous/papillary 1546 (8.6)
Unspecified adenocarcinoma 1232 (6.8)
Other histology 651 (3.6)
Laterality:
Left 9094 (50.4)
Right 8956 (49.6)
Year of diagnosis:
1991 277 (1.5)
1992 551 (3.1)
1993 675 (3.7)
1994 803 (4.5)
1995 1019 (5.7)
1996 1151 (6.4)
1997 1332 (7.4)
1998 1419 (7.9)
1999 1551 (8.6)
2000 2913 (16.1)
2001 3136 (17.4)
2002 3223 (17.9)
Hormone use:
No 10 935 (60.6)
Yes 7101 (39.4)
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patients’ characteristics.
During follow-up 734 (4%) women experienced
local recurrences after radiotherapy. An adjusted Cox
model showed that an interval to radiotherapy of over
six weeks was significantly associated with an
increased hazard for local recurrence (hazard ratio
1.19, 95% confidence interval 1.01 to 1.39, P=0.033).
Other factors independently associated with local
recurrenceincludedHispanicethnicity,tumourhistol-
ogy, left sided laterality, lack of hormone receptor
expression, increased tumour grade, and earlier year
of diagnosis (table 3). When we adjusted for the same
variables, the interval defined as days to start of radio-
therapy was more strongly correlated with local recur-
rence (P=0.004) (table 4). Adjusted hazard ratios with
interval dichotomised at different thresholds sup-
ported a continuous relation between interval and
local recurrence (fig 1). Results did not change signifi-
cantly when we excluded patients with stage 0 cancer
(table 4)orthosewithmissingcomorbiditycalculation
(hazard ratio 1.18, 1.01 to 1.39, P=0.041).
Confirmatory analyses suggested that the results
were also unchanged when we added a propensity
score predicting likelihood of receiving radiotherapy
after six weeks to the model (1.19, 1.01 to 1.39,
P=0.035), or when we studied the effect of interval to
radiotherapy within similar propensity strata. In addi-
tion, adjusted instrumental variable analysis showed
that starting radiotherapy after six weeks was asso-
ciated with a 0.96% absolute increase in local recur-
rence (P=0.026).
Over a quarter (26.3%) of the overall cohort waited
more than six weeks from last breast surgeryto start of
radiotherapy. In multivariable analysis (table 5),
greater comorbidity, being non-white, Hispanic ethni-
city, residence outsideof thesouthernstates,historyof
low income, having affected nodes, and more recent
year of diagnosis were independently associated with
startingradiotherapyaftersixweeks.Secondaryanaly-
sisshowedsignificantinteractionbetweenregionofthe
country and treatment year (P<0.001; fig 2).
DISCUSSION
Summary of findings
In olderwomenwithbreastcancer whodonot receive
chemotherapytheintervalfrombreastconservingsur-
gerytoradiotherapyaffectstheriskoflocalrecurrence.
Women who start radiotherapy more than six weeks
after surgery are more likely to have local recurrence.
The association is stronger when the interval is mea-
sured as days to radiotherapy, rather than dichoto-
mised at six weeks. This finding suggests that there is
no particular threshold, but instead a continuous rela-
tion between time to radiotherapy and local recur-
rence. Because the absolute risk of local recurrence is
low,however,differencesintheratesofrecurrenceare
small. Our instrumental variable analysis showed that
intervals over six weeks are associated with a 0.96%
increase in recurrence at five years.
Comparison with other studies
Previous studies that have examined interval to radio-
therapy as a dichotomous variable have also provided
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Fig 1 | Adjusted hazard ratios for local recurrence with varying
dichotomous thresholds. Numbers below graph reflect
patients who received radiotherapy after threshold
Table 3 |Factors significantly associated with local
recurrence in multivariable regression analysis in addition to
age and preinvasive or in situ (stage 0) carcinoma
Variable
Hazard ratio*
(95% CI) P value
Interval >6 weeks: 1.19 (1.01 to 1.39) 0.033
Age (per each additional year of age) 0.99 (0.98 to 1.01) 0.198
Hispanic:
No 1.0 (reference)
0.006
Yes 1.61 (1.14 to 2.27)
Tumour grade:
Low 1.0 (reference)
<0.001
Intermediate 1.39 (1.12 to 1.73)
High 1.75 (1.37 to 2.23)
Unknown 1.52 (1.19 to 1.95)
Progesterone receptor status:
Positive 1.0 (reference)
0.014
Negative 1.37 (1.13 to 1.66)
Borderline 1.67 (0.79 to 3.53)
Unknown 1.04 (0.85 to 1.27)
Histology:
Ductal 1.0 (reference)
0.010
Lobular 1.00 (0.75 to 1.35)
Mixed ductal/lobular 1.07 (0.78 to 1.48)
Tubular/medullary/mucinous/
papillary
1.26 (0.97 to 1.63)
Unspecified adenocarcinoma 1.61 (1.24 to 2.08)
Other histology 0.83 (0.48 to 1.46)
Preinvasive or in situ (stage 0) carcinoma:
No 1.0 (reference)
0.419
Yes 1.11 (0.86 to 1.42)
Year (per each later year of diagnosis) 0.95 (0.92 to 0.97) <0.001
Laterality:
Right 1.0 (reference)
0.016
Left 1.20 (1.03 to 1.38)
*Adjusted for each of the variables presented in table.
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be continuous. Across these studies, the effect of time
to radiotherapy on local recurrence increased the
longer the interval examined, consistent with our
observationofincreasedhazardwithlongerthresholds
(fig 1). For example, the hazard ratio in our analysis
with a threshold of six weeks was 1.19 (1.01 to 1.39).
A meta-analysis with a longer threshold of 9-16 weeks
after surgery found increased odds of 1.62 (1.21 to
2.16) for recurrence relative to patients treated within
eight weeks.
14 A population based study in Quebec
that examined the longer threshold of 12 weeks after
surgery was associated with a higher odds ratio for
local failure of 1.75 (1.00 to 3.08).
16 And a population
based study from British Columbia found a hazard
ratio of 2.00 (0.79 to 5.08) for local recurrence in
women who received radiotherapy after 20 weeks.
Because of our larger sample size, our analysis had
greater powerto detect smalldifferences in recurrence
than previous studies, thus allowing us to identify a
significant difference associated with shorter
delays.
13-16 Our study also provides further insight
into the nature of the relation between interval and
recurrence—namely,thattheeffectiscontinuouswith-
out a single threshold time.
Implications for survival
Because of the long natural course of early breast can-
cer, our mean follow-up of 5.4 years was not sufficient
to allow us to examine the effect of time to radio-
therapy on survival. Differences in mortality attributa-
ble to local recurrence in breast cancer cannot be
detected until 10-15 years after treatment.
17 Rando-
mised studies, however, support a robust association
betweenlocalrecurrenceandoverallsurvivalinbreast
cancerandsuggestthatforeveryfourlocalrecurrences
prevented through improved local treatment, one
death from breast cancer is avoided.
17 Therefore, our
findings with respect to the effect of longer interval to
radiotherapy on increased local recurrence could lead
to compromised survival.
Strengths and limitations
Because of its size, the linked dataset gave us greater
power to detect an association between time to radio-
therapy and local recurrence, but it also limited our
analysis to patients aged over 65. It seems reasonable
tohypothesisethatourfindingsmightbegeneralisable
to younger women. Previous studies that included
youngerwomenyieldedconsistentresults.
1316Further-
more, a meta-analysis of radiotherapy after breast
conserving surgery showed similar proportional
reductions across age groups.
17 In fact, because
younger age has been shown to be an independent
risk factor for local recurrence after breast conserving
surgery,
28 the association between interval to radio-
therapy and local recurrence could be even more pro-
nounced in younger patients.
Medicare claims are submitted for billing not
research purposes, and the determination of interval
to radiotherapy might not be precise. We attempted
to increase the accuracy of the definition of interval to
radiotherapy by restricting the analysis to those with a
treatment planning billing date from three weeks
before to seven days after initiation of radiotherapy,
but in doing so we might have excluded radiation
departmentswithdelaysinthetreatmentplanningpro-
cess.Wealsohadnoinformationaboutthestatusofthe
surgical margin and dose of radiation, both of which
might modulate the effect of interval on local recur-
rence. There is some evidence that women with
affected margins might receive higher doses of radia-
tion and receive radiotherapy closer to time of
surgery.
11 If this were true in our cohort, however,
our results would be biased towards the null and our
detected association between interval and local recur-
rence would be underestimated. Moreover, we con-
trolled for year of diagnosis in our analysis to mitigate
the effect of any secular trends in evaluation and status
of the surgical margin.
In addition, because local recurrence after radio-
therapy is a relatively rare event, we included women
with stage 0 and node positive disease to increase the
power of our analysis. Our results were essentially
unchanged when we restricted the analysis to women
with invasive disease. Our main outcome measure,
local recurrence, was largely identified by a mastect-
omy procedure requiring women to be well enough
to undergo surgery for local recurrence to be captured
and might therefore not be completely sensitive for
capture of local recurrence. We attempted to help to
ensure capture of our outcome and increase the like-
lihood of receiving adequate initial treatment by limit-
ing the analyses to those women who survived two
years from radiotherapy, and recurrence rates in our
analysis are comparable with those reported for true
recurrences with radiotherapy after breast conserving
Table 4 |Adjusted hazard ratios for local recurrence in multivariable analyses
Definition of interval
Stage 0-II Stage I-II
HR (95% CI)
P
value HR (95% CI) P value
>6 weeks 1.19 (1.01 to 1.39) 0.033 1.14 (0.96 to 1.36) 0.139
Days to start of radiotherapy 1.005(1.002to1.008) 0.004 1.005(1.001to1.009) 0.016
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Fig 2 | Regional variation in percentage of patients with
interval longer than six weeks over period studied
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29 Additionally, although the linked database
intentionally oversamples minority populations, our
study cohort had fewer minorities than the overall US
population, consistent with the lower average age and
decreased likelihood of receipt of breast conserving
surgery and radiotherapy among non-white US
populations.
30-32
We did not study the question of timing of radio-
therapy relative to chemotherapy. A randomised trial
varying the sequence of chemotherapy and radio-
therapy, however, did not find any difference in local
recurrence between the groups,
33 suggesting that the
effect of time from surgery to radiation might be com-
parable with the time from completion of chemother-
apy to the start of radiotherapy. Additionally, many of
thewomeninourdatasetdidnotreceiveaxillarynodal
surgery, evaluation of hormonal status, or histological
grading consistent with other analyses of practice pat-
terns during the era studied.
34 These omissions could
alsoindicatethatsomewomendidnotreceiveoptimal
radiotherapy.Wecontrolledforyearinouranalysisto
mitigate the effect of bias caused by secular trends in
improved practice patterns. Beyond previous partici-
pation in state based insurance plans targeted at low
income patients, we did not have individual measures
of socioeconomic status, although we did test the
significance of ecological measures of socioeconomic
status at the census tract level. Finally, although we
attempted to discern any effect of bias on our results
by using three different modelling techniques, we can-
not exclude the possibility that there might be addi-
tional factors associated with both time to start of
radiotherapy and local recurrence, which our dataset
did not enable us to study and which might confound
our results.
Sources of delay
The best intervention to reduce delay depends on the
factors responsible for that delay. Difficulties at the
patient level might be addressed through navigation
programmes. In contrast, inefficient processes in
pathology review or referral might best be addressed
through institutional quality improvement efforts in
multidisciplinary coordination. Finally, limitation in
radiotherapy capacity would probably require invest-
mentstoincreasestaffandfacilities,orpossiblytechni-
ques to increase existing capacity such as
hypofractionation or brachytherapy.
Our analysis of factors associated with increased
time to radiotherapy might provide insight into one
source of delay. The use of breast conserving surgery
increased during the period studied,
3135 and we found
thatmorerecentyearofdiagnosiswasasignificantpre-
dictor of increased interval to radiotherapy, but the
effect varied by region of the US. In the northeast, the
proportion of women whose radiation started more
than six weeks after surgery almost doubled, from
23.8% during 1991-2 to 42.0% during 2001-2. In con-
trast,inthesouthernstatesoftheUS,wheretheratesof
breast conservation were the lowest,
30 there was little
or no increase in the proportion of women receiving
radiation after six weeks over the sameperiod. Longer
times to radiotherapy during recent years and in
regions of the US known to have increased use of
breast conserving surgery suggest limitations in capa-
city of radiation delivery. Indeed, our instrumental
variableanalysisshowed an associationbetweeninter-
val to radiotherapy and longer distances to treatment
facility,providingfurtherindirectevidencethatlackof
availability of radiotherapy is contributing to delays.
Conclusions and policy implications
The implication of a continuous relation between start
of radiotherapy and local recurrence is that there is no
“safe”thresholdintermsofwaitingtimeandthatradio-
therapyshouldthereforebestartedassoonaspossible.
The cost of increasing capacity to ensure uniformly
short waiting times could be substantial. These costs
would need to be weighed against the small absolute
benefit in local recurrence that might be the result of
the investment. But given the known negative impact
of local recurrence on overall survival and the large
numbers of women treated with radiotherapy for
breastcancer,itseemsappropriatetoconsiderwhether
this is a price we should be prepared to pay.
Table 5 |Factors significantly associated with interval to
radiotherapy of over six weeks in multivariable logistic
regression analysis
Variable
Odds ratio
(95% CI) P value
Charlson score:
0 1.0 (reference)
0.030
1 1.11 (1.02 to 1.21)
2 1.12 (0.93 to 1.33)
≥3 0.89 (0.72 to 1.09)
Race:
White 1.0 (reference)
<0.001 Black 1.45 (1.24 to 1.68)
Other 0.94 (0.79 to 1.12)
Hispanic:
No 1.0 (reference)
0.006
Yes 1.29 (1.08 to 1.54)
State buy-in:
No 1.0 (reference) <0.001
Yes 1.27 (1.15 to 1.42)
Region:
South 1.0 (reference)
<0.001
Northeast 1.66 (1.46 to 1.88)
Midwest 1.31 (1.15 to 1.49)
West 1.35 (1.20 to 1.52)
Positive nodes:
0 1.0 (reference)
<0.001
1-3 or unknown 1.21 (1.06 to 1.37)
≥4 1.23 (0.81 to 1.87)
Not examined 0.76 (0.70 to 0.81)
Unknown 0.91 (0.79 to 1.66)
Per each additional year after 1991 1.07 (1.05 to 1.08) <0.001
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Previous studies regarding the effect of interval to radiotherapy in women treated for breast
cancer have had mixed findings
WHAT THIS STUDY ADDS
Usingalargepopulationbaseddatabase,wefoundanincreaseintheriskoflocalrecurrence
with longer interval to radiotherapy
The relation between interval to radiation and local recurrence seems to be continuous
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